Loading...
•
Jun 30, 2022
CervoMed Q2 2022 Earnings Report
Diffusion Pharmaceuticals reported financial results for the second quarter of 2022 and provided a business update.
Key Takeaways
Diffusion Pharmaceuticals reported positive results from its Altitude Trial and aligned with the FDA on an innovative GBM Trial design. The company ended the quarter with $28.5 million in cash, cash equivalents and marketable securities, expected to fund operations into the first quarter of 2024.
Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022.
Reported Positive Effects in TSC Altitude Trial.
Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities.
Expected Cash Runway into First Quarter of 2024
Forward Guidance
The company expects its cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...